|
1
|
Jiang Y, Chen M, Nie H and Yuan Y: PD-1
and PD-L1 in cancer immunotherapy: Clinical implications and future
considerations. Hum Vaccin Immunother. 15:1111–1122.
2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ma X, Zhang Y, Wang S, Wei H and Yu J:
Immune checkpoint inhibitor (ICI) combination therapy compared to
monotherapy in advanced solid cancer: A systematic review. J
Cancer. 12:1318–1333. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Robert C: A decade of immune-checkpoint
inhibitors in cancer therapy. Nat Commun. 11(3801)2020.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Tang SQ, Tang LL, Mao YP, Li WF, Chen L,
Zhang Y, Guo Y, Liu Q, Sun Y, Xu C and Ma J: The pattern of time to
onset and resolution of immune-related adverse events caused by
immune checkpoint inhibitors in cancer: A pooled analysis of 23
clinical trials and 8,436 patients. Cancer Res Treat. 53:339–354.
2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Herrmann SM and Perazella MA: Immune
checkpoint inhibitors and immune-related adverse renal events.
Kidney Int Rep. 5:1139–1148. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Giglio S, Montini G, Trepiccione F,
Gambaro G and Emma F: Distal renal tubular acidosis: A systematic
approach from diagnosis to treatment. J Nephrol. 34:2073–2083.
2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hu F, Zhai Y, Yuan L, Liang J, Xu J, Guo
X, Zhou X, Lin Z, Sun J, Ye X and He J: Renal toxicities in immune
checkpoint inhibitors with or without chemotherapy: An
observational, retrospective, pharmacovigilance study leveraging US
FARES database. Cancer Med. 10:8754–8762. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
El Bitar S, Weerasinghe C, El-Charabaty E
and Odaimi M: Renal tubular acidosis an adverse effect of PD-1
inhibitor immunotherapy. Case Rep Oncol Med.
2018(8408015)2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Charmetant X, Teuma C, Lake J, Dijoud F,
Frochot V and Deeb A: A new expression of immune checkpoint
inhibitors' renal toxicity: When distal tubular acidosis precedes
creatinine elevation. Clin Kidney J. 13:42–45. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Herrmann SM, Alexander MP, Romero MF and
Zand L: Renal tubular acidosis and immune checkpoint inhibitor
therapy: An immune-related adverse event of PD-1 inhibitor-A report
of 3 cases. Kidney Med. 2:657–662. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Atiq SO, Gokhale T, Atiq Z, Holmes R and
Sparks MA: A case of pembrolizumab induced distal renal tubular
acidosis. J Onco Nephrol. 5:23–26. 2021.
|
|
12
|
Doodnauth AV, Klar MM, Malik ZR, Patel KH
and McFarlane SI: A rare presentation of checkpoint inhibitor
induced distal RTA. Case Rep Oncol Med.
2021(7406911)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bertholet-Thomas A, Guittet C,
Manso-Silván MA, Castang A, Baudouin V, Cailliez M, Di Maio M,
Gillion-Boyer O, Golubovic E, Harambat J, et al: Efficacy and
safety of an innovative prolonged-release combination drug in
patients with distal renal tubular acidosis: An open-label
comparative trial versus standard of care treatments. Pediatr
Nephrol. 36:83–91. 2021.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Uras N, Karadag A, Karabel M and Tatli MM:
Is bicarbonate solution tolerated better than Shohl's solution in
neonatal renal tubular acidosis? Pediatr Nephrol. 22:152–153.
2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Batlle D and Haque SK: Genetic causes and
mechanisms of distal renal tubular acidosis. Nephrol Dial
Transplant. 27:3691–3704. 2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wagner CA, Finberg KE, Breton S,
Marshansky V, Brown D and Geibel JP: Renal vacuolar
H+-ATPase. Physiol Rev. 84:1263–1314. 2004.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Batlle DC, Hizon M, Cohen E, Gutterman C
and Gupta R: The use of the urinary anion gap in the diagnosis of
hyperchloremic metabolic acidosis. N Engl J Med. 318:594–599.
1988.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Battistone MA, Nair AV, Barton CR,
Liberman RN, Peralta MA, Capen DE, Brown D and Breton S:
Extracellular adenosine stimulates vacuolar ATPase-dependent proton
secretion in medullary intercalated cells. J Am Soc Nephrol.
29:545–556. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Menzies RI, Tam FW, Unwin RJ and Bailey
MA: Purinergic signaling in kidney disease. Kidney Int. 91:315–323.
2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Giordan Q, Salleron J, Vallance C, Moriana
C and Clement-Duchene C: Impact of antibiotics and proton pump
inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint
inhibitors. Front Immunol. 12(716317)2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen B, Yang C, Dragomir MP, Chi D, Chen
W, Horst D, Calin GA and Li Q: Association of proton pump inhibitor
use with survival outcomes in cancer patients treated with immune
checkpoint inhibitors: A systematic review and meta-analysis. Ther
Adv Med Oncol. 14(17588359221111703)2022.PubMed/NCBI View Article : Google Scholar
|
